首页> 美国卫生研究院文献>Oncotarget >KRAS NRAS and BRAF mutations detected by next generation sequencing and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy

【2h】

KRAS NRAS and BRAF mutations detected by next generation sequencing and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy

机译：通过一线FIr-B / FOx加贝伐单抗（BEV）进行三联化疗的下一代测序检测到的KRASNRAS和BRAF突变以及转移性结直肠癌（MCRC）患者的临床差异

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundFirst line triplet chemotherapy/BEV significantly improved clinical outcome of MCRC. KRAS/NRAS/BRAF mutations were evaluated by next generation sequencing (NGS) in MCRC patients treated with first line FIr-B/FOx.

机译：背景一线三联线化疗/ BEV可显着改善MCRC的临床疗效。通过下一代测序（NGS）在接受一线FIr-B / FOx治疗的MCRC患者中评估了KRAS / NRAS / BRAF突变。

著录项

期刊名称 Oncotarget
作者
Gemma Bruera; Francesco Pepe; Umberto Malapelle; Pasquale Pisapia; Antonella Dal Mas; Daniela Di Giacomo; Giuseppe Calvisi; Giancarlo Troncone; Enrico Ricevuto;
展开▼
作者单位

展开▼
年(卷),期 2018(9),41
年度 2018
页码 26279–26290
总页数 12
原文格式 PDF
正文语种
中图分类肿瘤学;细胞生物学;
关键词
FIr-B/FOx intensive first line triplet chemotherapy plus bevacizumab metastatic colorectal cancer next generation sequencing RAS/BRAF mutations 50 genes panel;

机译：FIr-B / FOx密集型一线三联体化疗加贝伐单抗;转移性结直肠癌;下一代测序;RAS / BRAF突变;50个基因组;

相似文献

外文文献
中文文献
专利

1. Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease [J] . Gemma Bruera, Katia Cannita, Daniela Di Giacomo, BMC Medicine . 2012,第1期

机译：根据转移性疾病的扩展程度，KRAS基因型在接受强化三联化疗加贝伐单抗（FIr-B / FOx）治疗的转移性结直肠癌（MCRC）患者中的预后价值
2. Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) [J] . Gemma Bruera, Katia Cannita, Daniela Di Giacomo, BMC Medicine . 2013,第1期

机译：KRAS c.35 G的更差预后>接受强化三联化疗加贝伐单抗（FIr-B / FOx）治疗的突变型转移性结直肠癌（MCRC）患者
3. Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype [J] . Gemma Bruera, Katia Cannita, Aldo Victor Giordano, International journal of oncology . 2013,第1期

机译：根据二线治疗和KRAS基因型，转移至一线三联体化疗加贝伐单抗，FIr-B / FOx后转移性结直肠癌患者的预后差异
4. Isolation of Circulating Tumor Cells from Patients with Metastatic Colorectal Cancer Using Label-Free Microfluidic Technology for Enumeration and Detection of KRAS, BRAF, PIK3CA Mutation [C] . Haiyan Emily Liu, Evelyn Kidess-Sigal, Melanie Triboulet, International Molecular Medicine Tri-Conference. . 2016

机译：使用无标记微流体技术分离转移性结肠直肠癌患者的循环肿瘤细胞进行募准和检测KRA，BRAF，PIK3CA突变
5. Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease [O] . Gemma Bruera, Katia Cannita, Daniela Di Giacomo, 2012

机译：根据转移性疾病的扩展KRAS基因型在接受强化三联化疗加贝伐单抗（FIr-B / FOx）治疗的转移性结直肠癌（MCRC）患者中的预后价值
6. Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease [O] . Gemma Bruera, Katia Cannita, Daniela Di Giacomo, 2012

机译：根据转移性疾病的扩展，KRAS基因型在接受强化三联化疗加贝伐单抗（FIr-B / FOx）治疗的转移性结直肠癌（MCRC）患者中的预后价值

KRAS NRAS and BRAF mutations detected by next generation sequencing and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy

摘要

著录项

相似文献

相关主题

期刊订阅